A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

(2015) W.-C. Yen et al.   CLINICAL CANCER RESEARCH

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral  -Secretase Inhibitor PF-03084014

(2014) W. A. Messersmith et al.   CLINICAL CANCER RESEARCH

Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors

(2013) A. F. Schott et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors

(2012) Ian Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

(2012) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Selective  -Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design

(2010) P. Wei et al.   MOLECULAR CANCER THERAPEUTICS

The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism

(2009) Raphael Kopan et al.   CELL

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER